ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

  • Abstract Number: L16 • ACR Convergence 2023

    Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial

    Linyi Peng1, Yuxue nie1, Jiaxin Zhou1, Lijun Wu2, Fang Wang3, Xiaomei Chen4, Jieqiong Li1, Yu Peng1, Hui Lu1, Lidan Zhao1, Mengtao Li1, Yan Zhao1, Xiaofeng Zeng5, Yunyun Fei1 and Wen Zhang1, 1Peking Union Medical College Hospital,Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China, 2Xinjiang Uygur Autonomous Region People's Hospital, XinJiang, China, 3Beijing Hospital, Beijing, China, 4Xinjiang Uygur Autonomous Region People's Hospital, Wulumuqi, China, 5Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

    Background/Purpose: IgG4-related disease (IgG4-RD) is a fibroinflammatory disease. Remission induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy…
  • Abstract Number: L07 • ACR Convergence 2023

    3-year Results of Tapering TNFi to Withdrawal Compared to Stable TNFi Among Rheumatoid Arthritis Patients in Sustained Remission: A Multicenter Randomized Trial

    Kaja Kjørholt1, Nina Sundlisæter1, Anna-Birgitte Aga1, Joseph Sexton1, Inge Christoffer Olsen2, Åse Lexberg3, Tor Magne Madland4, Hallvard Fremstad5, Christian A. Høili6, Gunnstein Bakland7, Cristina Spada8, Hilde Haukeland9, Inger Myrnes Hansen10, Ellen Moholt1, Karen Holten1, Till Uhlig1, Tore Kvien1, Daniel Solomon11, Désirée van der Heijde12, Espen Haavardsholm1 and Siri Lillegraven1, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Nepal, 3Department of Rheumatology, Drammen Hospital, Vestre Viken HF, Drammen, Norway, 4Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, 5Department of Rheumatology, Møre og Romsdal Hospital Trust, Ålesund, Norway, 6Department of Rheumatology, Østfold Hospital Trust, Moss, Norway, 7Department of Rheumatology, University Hospital of North Norway, Tromsø, Norway, 8Department of Rheumatology, Revmatismesykehuset AS, Lillehammer, Norway, 9Department of Rheumatology, Martina Hansens Hospital, Bærum, Norway, 10Deptartment of Rheumatology, Helgelandssykehuset, Mo i Rana, Norway, 11Division of Rheumatology, Brigham and Women's Hospital, Newton, MA, 12Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands

    Background/Purpose: Tapering of tumor necrosis factor inhibitor (TNFi) treatment in patients who have reached sustained remission is debated in current guidelines, and further data are…
  • Abstract Number: 0331 • ACR Convergence 2023

    Assessment of Patient Adherence to “Sick Day Rules”: A Cross-sectional Study of Rheumatology Outpatients Prescribed Immunosuppressive Medications

    Mervè Aksoy1, Pamela Gonzalez Manrique2, Heinrich-Karl Greenblatt1 and Katarzyna Gilek-Seibert1, 1Roger Williams Medical Center, Providence, RI, 2Roger Williams Medical Center, North Providence, RI

    Background/Purpose: Rheumatology outpatients receiving immunosuppressive medications (IS) inevitably develop acute infections. Expert guidance, in accordance with usual clinical practice, recommends counseling patients on “sick day…
  • Abstract Number: 0438 • ACR Convergence 2023

    Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review

    Swetha Ann Alexander1, Gordon Starkebaum2, Diana Louden2, Grant Hughes2 and Namrata Singh3, 1University of Utah Health, Salt Lake City, UT, 2University of Washington, Seattle, WA, 3University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid Arthritis (RA) patients have an increased risk of developing lymphoma compared to the general population. This increased risk is believed to be linked…
  • Abstract Number: 0678 • ACR Convergence 2023

    Benralizumab in Eosinophilic Granulomatosis with Polyangiitis

    Adrien Cottu1, Matthieu Groh2, Charlène Desaintjean3, Sylvain Marchand-Adam4, Loic Guillevin5, Xavier Puéchal6, Estibaliz Lazaro7, Maxime Samson8, Camille Taillé9, Cécile-Audrey Durel10, Elisabeth Diot11, Sarah Nicolas11, Laurent Guilleminault12, Mikael Ebbo13, Pascal Cathébras14, Clairelyne Dupin9, Halil Yildiz15, Nabil Belfeki16, Gregory Pugnet17, Pierre Chauvin18, Stephane Jouneau19, François Lifermann20, Jean-Philippe Martellosio21, Vincent Cottin22 and Benjamin Terrier23, 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, 3Department of Respiratory Diseases, Hôpital Louis Pradel, Lyon, France, 4CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, 5University Paris Descartes, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 7Bordeaux Hospital University, Pessac, France, 8Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 9AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, 10CHU Lyon, Lyon, France, 11Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, 12Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, 13Aix Marseille Univ, APHM, hôpital de la Timone, Internal Medicine Department, Marseille, France, 14Department of Internal medicine, Hôpital Nord, CHU St Etienne, Saint-Etienne, France, 15Saint Luc Hospital, Bruxelles, Belgium, 16Service de Médecine Interne et Immunologie Clinique. Groupe Hospitalier Sud Île de France, Melun, France, 17CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 18Department of Respiratory Diseases, Rennes University Hospital, Rennes, France, 19Amicus, Boca Raton, FL, 20Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, 21Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, 22Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 23Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Gucocorticoid (GC)-dependant asthma and ENT exacerbations may persist in more than 80% of eosinophilic granulomatosis with polyangiitis (EGPA). The MIRRA trial demonstrated the efficacy…
  • Abstract Number: 1292 • ACR Convergence 2023

    Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera2, Beatriz Vellón2, Rocio Guzman2, Tomás Cerdó2, Rafaela Ortega Castro3, Jerusalem Calvo4, Mª Angeles Aguirre5, Pedro Segui2, Ivan Arias de la Rosa6, Maria del Carmen Abalos-Aguilera7, Desiree Ruiz-Vilchez2, Christian Merlo-Ruiz2, Jose Javier Perez-Venegas8, Javier Godoy9, Dolores Ruiz-Montesinos10, Carmen Dominguez8, Carlos Rodriguez-Escalera11, Carmen Romero-Barco12, Antonio Fernandez-Nebro12, Natalia Mena Vazquez13, Julia Uceda Montañez14, Charo Santos14, Nuria Barbarroja15, Eduardo Collantes Estévez16, Mª del Mar Malagon2, Alejandro Escudero Contreras4 and Carlos Perez-Sanchez17, 1IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 3Hospital Reina Sofía, Cordoba, Spain, 4Reina Sofia University Hospital, Córdoba, Spain, 5Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, 7Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 8Virgen Macarena University Hospital, Sevilla, Spain, 9Jaen University Hospital, Jaen, Spain, 10Hospital Universitario Virgen Macarena, Sevilla, Spain, 11Virgen de la Victoria Hospital, Malaga, Spain, 12Hospital Regional Universitario de Málaga, Malaga, Spain, 13IBIMA, Málaga, Spain, 14Hospital Virgen de Valme, Sevilla, Spain, 15University of Cordoba, Córdoba, Spain, 16Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, 17IMIBIC, Córdoba, Spain

    Background/Purpose: Lipid metabolism impacts immune cell plasticity, activation, differentiation, and function, making the analysis of the lipidomic profile crucial in understanding chronic inflammatory diseases like…
  • Abstract Number: 1556 • ACR Convergence 2023

    Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome

    Sinem Nihal Esatoglu1, Sabriye Guner1, Sevim Guler2, Gulen Hatemi1, Nuray Kepil3, Yusuf Ziya Erzin4, Aykut Ferhat Celik4 and Ibrahim Hatemi4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pathology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey

    Background/Purpose: Gastrointestinal involvement of Behçet's syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics,…
  • Abstract Number: 2143 • ACR Convergence 2023

    Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study

    Maya Buch1, Daniel Aletaha2, Roberto F. Caporali3, Bernard G. Combe4, Hendrik Schulze-Koops5, Jacques-Eric Gottenberg6, Yoshiya Tanaka7, Ricardo Blanco8, Tsutomu Takeuchi9, Edmund V. Ekoka Omoruyi10, Katrien Van Beneden11, Vijay Rajendran12, Chris Watson13, Francesco De Leonardis14 and Paul Emery15, 1University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, 2Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, 4Department of Rheumatology, Montpellier University, Montpellier, France, 5Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany, 6Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, 7University of Occupational and Environmental Health, Kitakyushu, Japan, 8Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 9Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 10Biostatistics, Galapagos NV, Mechelen, Belgium, 11Medical Safety, Galapagos NV, Mechelen, Belgium, 12Clinical Research, Galapagos NV, Mechelen, Belgium, 13Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, 14Medical Affairs, Galapagos GmbH, Basel, Switzerland, 15Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: In the treatment of RA, JAK inhibitors are a valuable option to meet remission or low disease activity (LDA) treatment targets following an inadequate…
  • Abstract Number: 2246 • ACR Convergence 2023

    Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan

    Lars Erik1, Ahmed Soliman2, Dominic Nunag3, Ralph Lippe4, Matthew Davis3 and Mitsumasa Kishimoto5, 1Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 2AbbVie, Inc., North Chicago, IL, 3Medicus Economics, LLC, Milton, MA, 4AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 5Kyorin University School of Medicine, Yokohoma, Japan

    Background/Purpose: The national prevalence of PsA among patients (pts) with psoriasis (PsO) in Japan is estimated to be 14.3%. Risankizumab (RZB) was approved for the…
  • Abstract Number: 0347 • ACR Convergence 2023

    Towards Effective Shared Decision Making – Development and Validation of a Prediction Model for Personalized Probabilities of Side Effects in the Initial Treatment of Juvenile Idiopathic Arthritis

    Jonathan Park1, Thomas Loughin2, Andrew Henrey2 and Jaime Guzman3, 1Western University, London, ON, Canada, 2British Columbia Children's Hospital, Vancouver, BC, Canada, 3British Columbia Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: Clinical practice guidelines for Juvenile Idiopathic Arthritis (JIA) emphasize the importance of adapting guideline recommendations to each individual patient through shared decision-making among patients,…
  • Abstract Number: 0444 • ACR Convergence 2023

    Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis

    Chie Watai1, Kazuoki Tsuruda2, Yoshinori Tsumura1 and Daisuke Tasaki1, 1Teijin Pharma Limited, Chiyoda City Tokyo, Japan, 2Teijin America, Inc., Sausalito, CA

    Background/Purpose: TCK-276 is a highly potent, orally active, and selective cyclin dependent kinase 4/6 (CDK4/6) inhibitor that is in development as a novel synthetic disease…
  • Abstract Number: 0751 • ACR Convergence 2023

    Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023

    Sharon Abada1, Jing Li1, Gary Tarasovsky2, Cherish Wilson3, Jinoos Yazdany1, Mary Whooley1 and Gabriela Schmajuk3, 1University of California San Francisco, San Francisco, CA, 2San Francisco VA, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA

    Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
  • Abstract Number: 1304 • ACR Convergence 2023

    Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy

    Vivian Bykerk1, Isabel Castrejon2, Vibeke Strand3, Stephanie Dahan4, Raul Castellanos-Moreira5, Leo Chen6 and Wayne Little4, 1Department of Rheumatology, Hospital for Special Surgery, New York, NY, 2Hospital Universitario Gregorio Marañón, Madrid, Spain, 3Stanford University, Palo Alto, CA, 4Bristol Myers Squibb, Princeton, NJ, 5Bristol Myers Squibb, Madrid, Spain, 6Syneos Health, Vancouver, BC, Canada

    Background/Purpose: RA is a chronic disease that can lead to irreversible damage and functional decline with delayed or inadequate treatment.1 Abatacept + MTX is effective…
  • Abstract Number: 1568 • ACR Convergence 2023

    Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis

    Sema Kaymaz-Tahra1, Ozun Bayindir Tsechelidis2, Burak Ince3, Ozlem Ozdemir Isik4, Muhammet Emin Kutu5, Ozlem Karakas6, Tuba Demirci Yildirim7, Zeliha Ademoglu8, Elif Durak Ediboglu9, Burcu Ceren Ekti Uludogan10, Can Ilgin11, Sule Yasar Bilge12, Timucin Kasifoğlu12, Servet Akar9, Hakan Emmungil8, Fatos Onen13, Ahmet Omma6, Nilufer Alpay Kanitez14, Ayten Yazici4, Ayse Cefle15, Murat Inanç16, Kenan Aksu17, Gökhan Keser17, Haner Direskeneli18 and fatma Alibaz-Öner19, 1Sancaktepe Prof Dr Ilhan Varank Training and Research Hospital, Istanbul, Turkey, 2Ottawa University, Ottawa, ON, Canada, 3Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, 4Kocaeli University Faculty of Medicine, Kocaeli, Turkey, 5Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, 6Ankara City Hospital, Ankara, Turkey, 7Dokuz Eylul University, Izmir, Turkey, 8Trakya University Faculty of Medicine, Edirne, Turkey, 9Katip Celebi University Faculty of Medicine, Izmir, Turkey, 10Osmangazi University Faculty of Medicine, Eskişehir, Turkey, 11Marmara University Faculty of Medicine, Istanbul, Turkey, 12Division of Rheumatology, Medical School, Osmangazi University, Eskişehir, Turkey, 13Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 14Koc University Faculty of Medicine, Istanbul, Turkey, 15Division of Rheumatology, Medical School, Kocaeli University, Kocaeli, Turkey, 16Istanbul University, Istanbul, Turkey, 17Division of Rheumatology, Medical School, Ege University, Izmir, Turkey, 18Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, 19Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Conventional disease-modifying anti-rheumatic drugs (cDMARDs) are recommended in addition to glucocorticoids (GC) for all active Takayasu's arteritis (TAK) patients as the first-line therapy. However,…
  • Abstract Number: 2146 • ACR Convergence 2023

    After JAK Inhibitor Failure, “Switching” or “Cycling”?

    Pablo Francisco Muñoz Martínez1, Laura Mas Sanchez2, Elena Grau Garcia3, Carmen Riesco Barcena3, Anderson Victor Huaylla Quispe3, Alba Maria Torrat Noves3, Daniel Ramos Castro3, Belen Villanueva Mañez3, Iago Alcantara Alvarez3, Samuel Leal Rodriguez3, Elvira Vicens Bernabeu3, Jose Eloy Oller Rodriguez3, Ines Canovas Olmos3, Ernesto Tovar Sugrañes3, Carmen Najera Herranz3, Isabel Martinez Cordellat3, Hikmat Charia3, Rosa Negueroles Albuixech3, Marta De la Rubia Navarro2, Luis Gonzalez Puig3, Jose Ivorra Cortes3 and Jose Andres Roman Ivorra4, 1Rheumatology Department. HUP La Fe, Sagunto, Spain, 2Rheumatology Department. HUP La Fe, Valéncia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitari i Politècnic la Fe, Valencia, Spain

    Background/Purpose: The appearance of JAK inhibitors (JAKi) in the last few years has proved a great clinical application in rheumatic pathology and it has become…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 40
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology